Cor Pulmonale

(10 Marks - MD Exam Answer)

Definition

Pathogenesis

• Destruction of the alveolar-capillary bed - reduces the cross-sectional area of the pulmonary vascular bed, raising resistance
• Lung hyperinflation (as in COPD) - compresses pulmonary vessels; may paradoxically reduce right ventricular size (the "cor pulmonale parvus" phenotype, seen in emphysema with hyperinflation)
• Increased blood viscosity - secondary polycythemia from chronic hypoxemia
• Endothelial dysfunction - in COPD, endothelial-derived nitric oxide production by pulmonary artery tissue is reduced, even in spirometrically mild stages, disrupting the balance between vasodilators (NO, prostacyclin) and vasoconstrictors (endothelin, serotonin pathways)

Etiology / Causes of Cor Pulmonale

Pathophysiology of Right Ventricular Failure

1. Compensatory hypertrophy - the RV wall thickens to maintain stroke volume against increased afterload
2. Dilation - as hypertrophy fails to compensate, RV dilates
3. Tricuspid annular dilation - causing tricuspid regurgitation, which compounds venous hypertension
4. Ventricular interdependence - RV dilation shifts the interventricular septum leftward, impairing LV filling
5. Neurohormonal activation - renin-angiotensin-aldosterone system (RAAS) activation causes sodium and water retention, leading to peripheral edema (poorly correlated with resting right atrial pressure)

Clinical Features

Symptoms

• Exertional dyspnea (most common, from underlying lung disease + reduced cardiac output)
• Fatigue, exertional presyncope
• Ankle swelling

Signs of Pulmonary Hypertension and RV Failure

• Elevated jugular venous pressure with prominent v-waves (tricuspid regurgitation)
• Right ventricular heave (left parasternal)
• Loud P2 (accentuated pulmonary component of S2)
• Tricuspid regurgitation murmur (pansystolic at left sternal border, louder on inspiration)
• Hepatojugular reflux, hepatomegaly
• Ascites (advanced disease)
• Peripheral pitting edema (late sign)
• Central cyanosis from hypoxemia

"Physical findings indicative of cor pulmonale are venous engorgement, edema, and physical findings of pulmonary hypertension and right ventricular failure including elevated venous pressure, accentuated pulmonic second heart sound, right ventricular heave, tricuspid regurgitation murmur, hepatojugular reflux, and ascites." - Fishman's Pulmonary Diseases and Disorders

Investigations

ECG

• Right axis deviation
• Right ventricular hypertrophy (R > S in V1, deep S in V5-6)
• P pulmonale (peaked P waves >2.5 mm in lead II)
• Right bundle branch block
• ECG signs of chronic cor pulmonale are a negative prognostic finding in COPD (Incalzi et al., cited in Murray & Nadel)

Chest X-Ray

• Central pulmonary artery enlargement (hilar fullness)
• Peripheral vascular pruning
• Cardiomegaly with RV prominence
• Features of the underlying lung disease

CT Chest

• PA to aortic diameter ratio >1.0 is a strong independent predictor of acute exacerbations in COPD (Murray & Nadel, block 14)
• In severe COPD, PA:aortic ratio significantly associates with resting pulmonary hypertension and outperforms echocardiogram as predictor of PH

Echocardiography

• Estimates pulmonary artery systolic pressure (PASP) via tricuspid regurgitation jet velocity (modified Bernoulli equation)
• Assesses RV size, function, wall motion, tricuspid annular plane systolic excursion (TAPSE)
• Limitation: Doppler echocardiographic measures of PASP correlate poorly with severity of pulmonary hypertension by right heart catheterization in COPD patients (Fishman's)

Right Heart Catheterization (Gold Standard)

• Confirms pulmonary hypertension (mean PA pressure >20 mmHg)
• Distinguishes pre- vs. post-capillary causes (PCWP <15 mmHg in cor pulmonale)
• Assesses vasoreactivity (acute vasodilator challenge with inhaled NO or adenosine)

Other

• Pulmonary function tests - confirm underlying lung disease, degree of obstruction/restriction
• ABG - assess hypoxemia and hypercapnia
• 6-minute walk test - functional capacity, correlates with prognosis
• Cardiac MRI - increasingly recognized as more probative for RV function than echo (Fishman's)

Prognosis

• Once cor pulmonale is clinically apparent, survival is markedly reduced in proportion to impairment of functional capacity
• If PA pressure exceeds 25 mmHg, average 5-year survival is diminished by 50% (Fishman's)
• Survival is further worsened by the presence of hypercapnia, severe airflow obstruction, and low exercise capacity

Management

1. Treat the Underlying Disease

• Bosentan in COPD patients with PH worsened hypoxemia and quality of life (randomized trial)
• Epoprostenol increased mortality in left ventricular dysfunction trials
• Sildenafil showed no benefit in left heart dysfunction (SIOVAC study)

2. Supplemental Oxygen - Cornerstone of Treatment

• Continuous long-term oxygen therapy (LTOT) is the primary treatment for cor pulmonale in hypoxemic COPD
• Relieves hypoxic pulmonary vasoconstriction, reduces PVR, improves cardiac output
• Lessens renal vasoconstriction, improving urinary sodium excretion
• Target: maintain SpO2 ≥90% at rest, with exertion, and during sleep
• Landmark trials: MRC trial and NOTT trial both showed LTOT improved survival in chronic hypoxic cor pulmonale complicating COPD (cited in Murray & Nadel)

3. Diuretics

• Essential for managing fluid retention and right heart failure
• Spironolactone for mild fluid retention (also modulates neurohormones)
• Loop diuretics (furosemide) for moderate-severe fluid overload
• Caution: over-diuresis causes volume depletion and electrolyte imbalances

4. Exercise Rehabilitation

• Patients should maintain as active a lifestyle as possible
• Recommendations to minimize exertion result only in deconditioning and worsen symptoms
• Randomized trials show exercise rehabilitation in PAH/CTEPH patients improves 6-minute walk distance more than pharmacologic treatments
• Pulmonary/cardiac rehabilitation programs recommended (Fishman's)

5. Immunizations

• Annual influenza vaccination
• 23-valent polysaccharide pneumococcal vaccine + 13-valent conjugate pneumococcal vaccine per protocol
• Important preventive measure in all patients with pulmonary hypertension and cor pulmonale (Fishman's)

6. Digitalis

• Role is unsettled in right heart failure
• IV digoxin (1 mg) produced modest CO increase in small series of PAH patients with RV failure
• Long-term data lacking; about 25% of patients in REVEAL registry used digoxin
• Many physicians avoid it due to insufficient evidence and toxicity risk (Fishman's)

7. Calcium Channel Blockers / Vasodilators

• Can dilate the pulmonary circulation but worsen hypoxemia in COPD-related cor pulmonale
• Benefit is not established in this population
• Role limited to patients with idiopathic PAH who demonstrate acute vasoreactivity (Fishman's)

8. Anticoagulation

• Used in CTEPH-associated cor pulmonale
• Role in COPD/ILD-related cor pulmonale not established

9. Treat Polycythemia if Present

• Traditionally considered common and a poor prognostic marker
• Recent cohort data indicate polycythemia is infrequent in hypoxemic COPD and has uncertain effect on outcomes (Fishman's)

Summary Points for Exam